Maria Marluce dos Santos Vilela

Prof. Dr. Maria Marluce dos Santos Vilela


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2000 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
VLVania Aparecida Leandro-Merhi
Vania Aparecida Leandro-Merhi
MVMaria Marluce dos Santos Vilela
Maria Marluce dos Santos Vilela
MSMarcos Nolasco da Silva
Marcos Nolasco da Silva
FLFábio Ancona Lopez
Fábio Ancona Lopez
AFAntônio de Azevedo Barros Filho
Antônio de Azevedo Barros Filho
CONTEXT: There are today only a limited number of studies defining growth parameters and nutritional status for HIV children. OBJECTIVE: To study the nutritional status of infants infected with the human immunodeficiency virus. TYPE OF STUDY: Longitudinal study. SETTING: Department of Pediatrics, Faculty of Medical Sciences, UNICAMP, Campinas, Brazil. PARTICIPANTS: One hundred and twenty-four children born to HIV infected mothers were evaluated from birth until the age of two years. They were subdivided into two groups: 71 infected children and 53 non-infected children. MAIN MEASUREMENTS: Growth was evaluated in both groups by comparing Z-scores for weight/age (w/a), length/age (H/a) and weight/length (w/H) (using the NCHS curves as reference). RESULTS: The Z-score analyses showed that there was a significant difference between the two groups for all the variables studied, except for the H/a value at 3 months of age and the W/H value at 21 months of age, which showed P > 0.05. CONCLUSIONS: The growth of infected infants was observed to be severely affected in comparison with that of seroreversed infants in the same age groups. Although clinical manifestations may take time to appear, the onset of growth changes begin soon after birth.

14 August 2021 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
LMLia Furlaneto Marega
Lia Furlaneto Marega
JSJanine S. Sabino
Janine S. Sabino
MPMarcus Vinicius Pedroni
Marcus Vinicius Pedroni
MTMarcelo Teocchi
Marcelo Teocchi
CLCarolina Lanaro
Carolina Lanaro
MVMaria Marluce dos Santos Vilela
Maria Marluce dos Santos Vilela

1 January 2022 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
NSNatascha Silva Sandy
Natascha Silva Sandy
LMLia Furlaneto Marega
Lia Furlaneto Marega
GBGiane Dantas Bechara
Giane Dantas Bechara
ARAdriana Gut Lopes Riccetto
Adriana Gut Lopes Riccetto
CBCarmem Bonfim
Carmem Bonfim
ELElizete Aparecida Lomazi
Elizete Aparecida Lomazi
Objective: To report two patients with very-early-onset inflammatory bowel disease (VEOIBD) secondary to interleukin-10 receptor (IL-10R) mutations, explore immunophenotyping data and plasma cytokine profile on these cases compared to healthy controls, and describe the phenotype of IL-10/IL-10R mutations based on a literature review. Case description: We report on two female infants referred to our tertiary center at the age of ten months, with severe colonic and perianal disease, as well as significant malnutrition, who had shown limited response to usual inflammatory bowel disease (IBD) therapy agents. In the first case, whole-exome sequencing (WES) revealed a homozygous (c.537G>A/p.T179T) mutation in exon 4 of the IL-10RA gene, while in the second patient, compound heterozygosity was identified, also in the IL-10RA gene (chr11:117.859.199 variant A>G/p.Tyr57Cys and chr11: 117.860.335 variant G>T/p.Val123Leu). Both patients underwent hematopoietic cell transplantation (HCT). Immunological work-up of these patients revealed increased IL-10 plasma levels and increased IgA. Comments: Our case reports disclose novel findings on plasma cytokine profile in IL-10R deficiency, and we describe the severe phenotype of IL-10/IL-10R deficiency that should be recognized by physicians.

13 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
JSJanine S. Sabino
Janine S. Sabino
MAMariene Ribeiro Amorim
Mariene Ribeiro Amorim
William SouzaWilliam Souza
William Souza
LMLia F. Marega
Lia F. Marega
LMLuciana Souto Mofatto
Luciana Souto Mofatto
MVMaria Marluce dos Santos Vilela
Maria Marluce dos Santos Vilela
Currently, there are no evidence-based treatment options for long COVID-19, and it is known that SARS-CoV-2 can persist in part of the infected patients, especially those with immunosuppression. Since there is a robust secretion of SARS-CoV-2-specific highly-neutralizing IgA antibodies in breast milk, and because this immunoglobulin plays an essential role against respiratory virus infection in mucosa cells, being, in addition, more potent in neutralizing SARS-CoV-2 than IgG, here we report the clinical course of an NFκB-deficient patient chronically infected with the SARS-CoV-2 Gamma variant, who, after a non-full effective treatment with plasma infusion, received breast milk from a vaccinated mother by oral route as treatment for COVID-19. After such treatment, the symptoms improved, and the patient was systematically tested negative for SARS-CoV-2. Thus, we hypothesize that IgA and IgG secreted antibodies present in breast milk could be useful to treat persistent SARS-CoV-2 infection in immunodeficient patients.

24 November 2020 in Jornal de Pediatria
Verified
Journal Article
Open access
MVMaria Marluce dos Santos Vilela
Maria Marluce dos Santos Vilela
Objective: This minireview gathers the scientific foundations of the literature on genetic errors in the development of the humoral immune system to help pediatricians suspect these defects. Sources: A systemic search using the PubMed MEDLINE database was performed for all Predominantly Antibody Deficiencies(PADs) described in the 2020 IUIS Expert Committee for PID classification system, combined with terms for hypogammaglobulinemia. Search terms for PADs were based on the listed names and affected genes as classified by the IUIS 2020. Abstracts of the results were reviewed to find relevant case series, review articles of PADs associated with infection, opportunistic infection, autoimmunity, cytopenias, malignancies, inflammatory diseases, neurological and respiratory diseases. References from relevant articles were further reviewed for additional references. Relevant findings were grouped inaccordance with the IUIS 2020 classification system. Clinical and genetic features, if known, were described. Data synthesis: PADs refer to impaired antibody production due to molecular defects intrinsic to B cells or a failure of interaction between B and T cells. The patients develop recurrent or chronic infection or respond to the antigens with dysregulation of the immune function, causing severe allergy, autoimmunity, inflammation, lymphoproliferation and malignancy. The diagnosis is a combined exercise of clinical and laboratory investigation similar to that performed by Bruton(1952). In the context of SARS-CoV-2 infection, the experience of XLA and CVID patients has been surprising. Variants in 39 genes were reported as causing PADs, but the clinical heterogeneity within each variant is not clear. Conclusion: Bruton (1952) used clinical expertise and protein electrophoresis to identify XLA. The IUIS(2020) committee used immunoglobulins and B lymphocyte to characterize PADs. Pediatricians should suspect it to detect it and prevent morbidities that can have an astonishing and irreversible impact on the child's life. (C) 2020 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.

8 August 2024 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
MTMarcelo Teocchi
Marcelo Teocchi
TEThaís de Andrade Eugênio
Thaís de Andrade Eugênio
LMLia Furlaneto Marega
Lia Furlaneto Marega
IQIsabella Quinti
Isabella Quinti
MVMaria Marluce dos Santos Vilela
Maria Marluce dos Santos Vilela
Introduction In X-linked agammaglobulinemia (XLA), the diversity of BTK variants complicates the study of genotype-phenotype correlations. Since BTK negatively regulates toll-like receptors (TLRs), we investigated if distinct BTK mutation types selectively modulate TLR pathways, affecting disease expression. Methods Using RT-qPCR, we quantified ten TLR signaling-related genes in XLA patients with missense (n=3) and nonsense (n=5) BTK mutations and healthy controls (n=17). Results BTK, IRAK2, PIK3R4, REL, TFRC, and UBE2N were predominantly downregulated, while RIPK2, TLR3, TLR10, and TLR6 showed variable regulation. The missense XLA group exhibited significant downregulation of IRAK2, PIK3R4, REL, and TFRC, and upregulation of TLR3 and/or TLR6. Conclusion Hypo-expression of TLR3, TLR6, and TLR10 may increase susceptibility to infections, while hyper-expression might contribute to chronic inflammatory conditions like arthritis or inflammatory bowel disease. Our findings shed light on the important inflammatory component characteristic of some XLA patients, even under optimal therapeutic conditions.